AMR Sept Banner v2

ASM Attends UN General Assembly

ASM President, Susan Sharp, Ph.D., joined global leaders at the United Nations General Assembly in New York today in a historical meeting to focus on the commitment to fight AMR.
Read

UN General Assembly Focuses on AMR

Leaders at the UN General Assembly draft a plan for coordinated, cross-cutting efforts to improve the current state of AMR.
Read

Superbugs are a 'Fundamental Threat'

If antibiotics were telephones, we would still be calling each other using clunky rotary dials and copper lines," Stefano Bertuzzi, CEO of ASM, told NBC News.
Read
Become a member today!
JOIN ASM
Submit Abstracts for Biothreats 2017
SUBMIT
Antibacterial Development Conference
REGISTER

Division of Global HIV/AIDS

 

1. DGA Drug Resistance Surveillance and Monitoring in resource-limited Settings  

C. Yang  

Research in the laboratory focuses on the development and implementation of HIV drug resistance genotyping tools and usage of these genotyping tools in the surveillance and monitoring of HIV drug resistance in resource-limited settings to minimize the development and transmission of HIV drug resistant strains in antiretroviral-treated and recently HIV-infected populations and to inform stakeholders and policy-makers on the effectiveness of HIV prevention, and care and treatment efforts in PEPFAR-supported countries. Specific research areas include 1) Surveillance and monitoring of HIV drug resistance development in PEPFAR-supported countries 2) Evaluation of resource-limited-setting friendly sample collection methodologies in the surveillance of HIV drug resistance in PEPFAR-supported countries, 3) Associations of HIV-1 subtypes and circulating recombinant forms on the development and persistence of HIV drug resistant mutations in countries where multiple subtypes and circulating recombinant forms are co-circulating and their impact on the efficacies of antiretroviral therapy.  

References

Zhang, J, Kang D, Fu J, Sun X, Lin B, Bi Z, Nkengasong NJ, and Yang C. Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed HIV type 1-infected patients in Shandong Province, China. AIDS Res Hum Retroviruses 26:99-103, 2010. 


Rottinghaus EK, Ugbenga R, Diallo K, Bassey O, Azeez A, DeVos J, Wurie I, Aberle-Grasse J, Nkengasong J, Knight N and Yang C. Evaluation of dried blood spots and dried plasma spots for HIV-1 viral load and drug-resistance genotyping in patients on antiretroviral therapy. Antivir Ther, 15 Suppl2:A148, 2010. 


Zhang J, Kang D, Sun X, Lin B, Fu J, Bi Z, Nkengasong J and Yang C. HIV-1 viral load measurement and PCR for drug resistance genotyping using dried blood spots and dried plasma spots collected from antiretroviral therapy (ART)-experienced patients. Antivir Ther, 15 Suppl2:A146, 2010. 


Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim A, Wadonda-Kabondo N, Aberle-Grasse J, Kibuka T, Ndumbe PM, Vedapuri A, Zhou Z, Chilima B and Nkengasong JN. Development and application of a broadly-sensitive dried-blood-spots-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol. 48:3158-64, 2010. 


Somi G, Kibuka T, Diallo K, Tuhuma T, Bennett D, Yang C, Kagoma C, Lyamuya E, Swai S, Kassim S. Surveillance of transmitted drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antiviral Therapy, Sup 2:77-82, 2008. Malawi HIV Drug Resistance Task Force.  


TPL_asm2013_SEARCH

118